Harrow, Inc. Common Stock (HROW) Stock
NASDAQ · HROW
30.33
Fundamentals
Market cap
$1.24B
Price / Earnings ratio
-33.3x
Price / Sales ratio
4.5x
Price / Book ratio
81.6x
Return on assets
-4.0%
Ex-Dividend date
N/A
Last payment date
N/A
Dividend amount
$0.00
Dividend yield
0.00%
Debt / Equity ratio
N/A
Recent news

MarketBeat
Harrow Q2 Earnings Call Highlights
NeutralHROWAugust 11, 2026
MarketBeatNeutral
Harrow Q2 Earnings Call Highlights
HROW

Zacks Investment Research
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
NeutralHROWAugust 11, 2026
Zacks Investment ResearchNeutral
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
HROW

Business Wire
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
NeutralHROWJuly 1, 2026
Business WireNeutral
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
HROW

Zacks Investment Research
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
NeutralHROWJune 11, 2026
Zacks Investment ResearchNeutral
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
HROW
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
Analyst Ratings
Strong Sell0
Sell0
Neutral0
Buy2
Strong Buy0
Financials
Performance
Revenue
Net income
Net margin %
2025
327M216M108M0
Debt & Balance Sheet
Total assets
Total liabilities
2025
479M316M158M0
Revenue to Profit
2025$272.3M
Revenue$0.0
Cost of revenue$0.0
Gross profit$0.0
Operating expenses$-5.1M
Net incomeEarnings
No data available
% positive news of 10 articles
published over the past 14 days
Latest news

MarketBeat
Harrow Q2 Earnings Call Highlights
NeutralHROWAugust 11, 2026
MarketBeatNeutral
Harrow Q2 Earnings Call Highlights
HROW

Zacks Investment Research
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
NeutralHROWAugust 11, 2026
Zacks Investment ResearchNeutral
Harrow (HROW) Reports Q2 Loss, Misses Revenue Estimates
HROW

Business Wire
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
NeutralHROWJuly 1, 2026
Business WireNeutral
Samsung Bioepis Relaunches BYOOVIZ® (ranibizumab-nuna) in the United States in Partnership with Harrow
HROW

Zacks Investment Research
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
NeutralHROWJune 11, 2026
Zacks Investment ResearchNeutral
HROW Stock Rises on Relaunch of Ophthalmology Drug Verkazia in the US
HROW

MarketBeat
Harrow Q1 Earnings Call Highlights
NeutralHROWMay 12, 2026
MarketBeatNeutral
Harrow Q1 Earnings Call Highlights
HROW

Zacks Investment Research
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
NeutralHROWMay 11, 2026
Zacks Investment ResearchNeutral
Harrow (HROW) Reports Q1 Loss, Lags Revenue Estimates
HROW

Zacks Investment Research
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
NeutralHROWMay 4, 2026
Zacks Investment ResearchNeutral
Analysts Estimate Harrow (HROW) to Report a Decline in Earnings: What to Look Out for
HROW

The Motley Fool
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
NeutralHROWMarch 24, 2026
The Motley FoolNeutral
A Major Investor Just Sold $7.8 Million in Harrow Stock -- Is This a Sell Signal?
HROW

Zacks Investment Research
Harrow (HROW) Misses Q4 Earnings Estimates
NeutralHROWMarch 3, 2026
Zacks Investment ResearchNeutral
Harrow (HROW) Misses Q4 Earnings Estimates
HROW

Zacks Investment Research
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth
NeutralHROWFebruary 23, 2026
Zacks Investment ResearchNeutral
Harrow (HROW) Reports Next Week: Wall Street Expects Earnings Growth
HROW
About Harrow, Inc. Common Stock
No description available.
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Employees373
CEOMr. Mark L. Baum J.D.
IPO DateSep 28, 2007
HeadquartersNashville, TN
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Mark L. Baum J.D. | CEO, Chairman of the Board & Founder | 1972 |
| Mr. Andrew R. Boll C.F.A., C.M.A. | President, CFO & Chief Accounting Officer | 1982 |
| Dr. Amir W. Shojaei Ph.D., Pharm.D. | Chief Scientific Officer | 1968 |
| Mr. Francis W. Mullery | President & CEO of Harrow's ImprimisRx Division | — |
| Mr. Michael D. Biega | Vice President of Investor Relations & Communications | — |
| Mr. Brett A. Burrell | Vice President of Legal & Compliance | — |
| Ms. Kim Barratt | Chief Talent Officer | — |
| Dr. Mark A. Mannebach Ph.D., R.Ph. | Head of Regulatory Affairs & Pharmacovigilance | — |
| Dr. Prashanth S. Annavajjhala | Chief of Staff | — |
| Mr. Patrick W. Sullivan | Chief Commercial Officer | 1976 |
Fundamentals
Valuation
Market cap$1.24B
Price-to-sales ratio4.50
Price-to-book value81.63
Price-earnings ratio-33.30
Return on Equity-34.00%
Return on Sales5.00%
Return on Assets-4.00%
PEG ratioN/A
Earnings Per Share
Earnings Per Share$-0.99
Income Statement
Average volume543,637
EBITDA$32.51M
1 year high (52w)$54.85
1 year low (52w)$28.54
Dividend
Ex dividend dateN/A
Dividend amount$0.00
Dividend yield0.00%
Last payment dateN/A
Dividend yield (TTM)N/A
Next earnings reportN/A
Solvency
Debt-to-equity ratioN/A
Technicals
OscillatorsSell5 Indicators
Moving AveragesStrong Sell12 Indicators
What the experts say
2 Wall Street Analyst Ratings
BUY
100% Buy
0% Hold
0% Sell
Target price
$54.00
Est return
60.05%
Seasonality
Monthly price change (%)| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2021 | +0.2 | +10.9 | -4.6 | -13.3 | ||||||||
| 2022 | -13.4 | -3.0 | -10.3 | -0.4 | +5.5 | +0.3 | -5.9 | +33.2 | +35.9 | -6.2 | -9.9 | +22.5 |
| 2023 | +1.6 | +18.1 | +15.3 | +20.3 | -27.1 | -2.4 | +20.3 | -28.2 | -7.2 | +3.2 | -31.4 | +20.3 |
| 2024 | -20.3 | +13.6 | +20.8 | -20.4 | +72.1 | +22.7 | +22.5 | +64.8 | +13.4 | +1.4 | -8.2 | -19.9 |
| 2025 | -16.0 | -5.9 | +3.8 | -0.8 | +12.4 | +1.9 | +3.2 | +24.9 | +27.7 | -21.9 | +16.2 | +23.2 |
| 2026 | -18.0 | +20.7 | -34.2 | +14.4 | -13.9 | +24.5 | -9.8 | -5.6 | -10.5 |



